Aspirin 75mg tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Aspirin

Available from:

Accord-UK Ltd

ATC code:

B01AC06

INN (International Name):

Aspirin

Dosage:

75mg

Pharmaceutical form:

Oral tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 02090000; GTIN: 5012617026842

Patient Information leaflet

148x210 Leaflet Reel Fed Profile (BST)
Dimensions:
Component:
Date Sent:
Technologist: TECHNICALLY APPROVED
Pharmacode:
JDE No.:
Aspirin Tablets
75mg x 28’s (UK)
148x210 (Reel Fed)
50974065
Leaflet for Blisters
5330
T. Hull
24/07/19
* Please note that ONLY Artwork Studio is permitted to make changes to
the above artwork.
No changes are permitted by any 3rd party other than added notes and
mark ups for required changes.
approved for print/date
PROOF ROUND
[e-mail]
Technical
Approval
NON PRINTING COLOURS
COLOURS
DATE SENT:
DATE RECEIVED:
Item number:
ORIGINATOR:
ORIGINATION DATE:
REVISION DATE:
REVISED BY:
DIMENSIONS:
MIN BODY TEXT SIZE:
SUPPLIER:
1.
2.
3.
4.
5.
6.
1.
2.
3.
FMD info
NA (not a carton)

No

Yes

Details
ACETYLSALICYLIC ACID (ASPIRIN) 75 MG 28 TABLET PIL - UK
Black
Profile/Text Safe Area
BBBA5627
25.07.2019
R.Paul
25.02.2021
R.Paul
148 x 210 (Reel Fed)
8.5pt
Accord Barnstaple
N/A
N/A
8
Version 2
01.11.2017
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE
BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on
to
others. It may harm them, even if their signs of illness are the same
as
yours.
• If you get any side effects, talk to your doctor or pharmacist.
This includes
any possible side effects not listed in this leaflet. See section 4.
• The full name of this medicine is Aspirin 75mg Tablets but within
the
leaflet it will be referred to as Aspirin Tablets.
WHAT IS IN THIS LEAFLET:
1
WHAT ASPIRIN TABLETS ARE AND WHAT THEY ARE USED FOR
2
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ASPIRIN TABLETS
3
HOW TO TAKE ASPIRIN TABLETS
4
POSSIBLE SIDE EFFECTS
5
HOW TO STORE ASPIRIN TABLETS
6
CONTENTS OF THE PACK AND OTHER INFORMATION
1
WHAT ASPIRIN TABLETS ARE AND WHAT THEY ARE USED FOR
Aspirin Tablets contain acetylsalicylic acid, which in low doses
belongs

Summary of Product characteristics

OBJECT 1
ASPIRIN 75MG TABLETS
Summary of Product Characteristics Updated 01-Mar-2021 | Accord-UK Ltd
•
1. Name of the medicinal product
•
2. Qualitative and quantitative composition
•
3. Pharmaceutical form
•
4. Clinical particulars
•
4.1 Therapeutic indications
•
4.2 Posology and method of administration
•
4.3 Contraindications
•
4.4 Special warnings and precautions for use
•
4.5 Interaction with other medicinal products and other forms of
interaction
•
4.6 Fertility, pregnancy and lactation
•
4.7 Effects on ability to drive and use machines
•
4.8 Undesirable effects
•
4.9 Overdose
•
5. Pharmacological properties
•
5.1 Pharmacodynamic properties
•
5.2 Pharmacokinetic properties
•
5.3 Preclinical safety data
•
6. Pharmaceutical particulars
•
6.1 List of excipients
•
6.2 Incompatibilities
•
6.3 Shelf life
•
6.4 Special precautions for storage
•
6.5 Nature and contents of container
•
6.6 Special precautions for disposal and other handling
•
7. Marketing authorisation holder
•
8. Marketing authorisation number(s)
•
9. Date of first authorisation/renewal of the authorisation
•
10. Date of revision of the text
1. Name of the medicinal product
Aspirin 75mg Tablets
2. Qualitative and quantitative composition
Each tablet contains 75 mg acetylsalicylic acid.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Tablet.
Oval, white, biconvex tablets, 9.0 x 5.0 mm, debossed with KM on one
side and plain on the other side.
4. Clinical particulars
4.1 Therapeutic indications
- Secondary prevention of myocardial infarction.
- Prevention of cardiovascular morbidity in patients suffering from
stable angina pectoris.
- History of unstable angina pectoris, except during the acute phase.
- Prevention of graft occlusion after Coronary Artery Bypass Grafting
(CABG).
- Coronary angioplasty, except during the acute phase.
- Secondary prevention of transient ischaemic attacks (TIA) and
ischaemic cerebrovascular accidents (CVA),
provided intracerebral haemorrhages